55301-13-8

Upstream product

• 3392-07-2 tert-butyl N-{2-[(2,5-dioxopyrrolidin-1-yl)oxy]-2-oxoethyl}carbamate 
• 64471-98-3 prolylglycine benzyl ester hydrochloride 
• 4530-20-5 BOC-glycine 
• 63496-06-0 L-prolylglycine benzyl ester 
• 3392-10-7 tert-butoxycarbonyl-L-proline N-hydroxysuccinimide ester 
• 1738-68-7 Gly-OBz 
• 31953-80-7 N-tert-butyloxycarbonyl-(2S)-prolyl-glycine benzyl ester 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 

Downstream Products

• 80463-63-4 H-Gly-Pro-Gly-OBzl hydrochloride 
• 80452-02-4 H-Gly-Pro-Gly-OBzl 
• 219575-90-3 Boc-Arg(Tos)-Ile-Gln-Arg(Tos)-Gly-Pro-Gly(OBzl) 
• 80451-92-9 Boc-Leu-Gly-Gly-Gly-Pro-Gly-OBzl 

Relevant academic research and scientific papers

Synthesis of Tn, sialyl Tn and HIV-1-derived peptide antigen conjugates having a lipid a analog as an immunoadjuvant for synthetic vaccines

Conjugates (3-5) of Tn, sialyl Tn and HIV-1-derived peptide antigen with a N-tetradecanoyl L-serine-β-alanine-containing D-glucosamine derivative, structurally related to lipid A, as an immunoadjuvant for the development of totally synthetic vaccines against cancers or HIV were synthesized. The mitogenic activity of compounds 3, 4 and 5 was stronger than that of lipid A analogs (1, 2).